Astria Therapeutics Inc
ATXS12.510USD
+0.080+0.64%
종가 11/07, 16:00（ET）시세는 15분 지연됩니다
705.99M시가총액
손실P/E TTM
자세한 내용은 Astria Therapeutics Inc 회사
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The Company owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.
Astria Therapeutics Inc 정보
종목 코드 ATXS
회사 이름Astria Therapeutics Inc
상장일Jun 25, 2015
CEODr. Jill C. Milne, Ph.D.
직원 수78
유형Ordinary Share
회계 연도 종료Jun 25
주소22 Boston Wharf Road
도시BOSTON
증권 거래소NASDAQ Global Market Consolidated
국가United States of America
우편 번호02210
전화16173491971
웹사이트https://astriatx.com/
종목 코드 ATXS
상장일Jun 25, 2015
CEODr. Jill C. Milne, Ph.D.
Astria Therapeutics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
263.32K
--
Mr. Noah Clauser
Mr. Noah Clauser
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Elizabeth Higgins
Ms. Elizabeth Higgins
Investor Relations
Investor Relations
--
--
Dr. Joanne T. Beck, Ph.D.
Dr. Joanne T. Beck, Ph.D.
Independent Director
Independent Director
--
--
Dr. Jill C. Milne, Ph.D.
Dr. Jill C. Milne, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Mr. Andrew Komjathy
Mr. Andrew Komjathy
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
--
--
Mr. Benjamin Scott Harshbarger
Mr. Benjamin Scott Harshbarger
Chief Legal Officer
Chief Legal Officer
--
--
Ms. Andrea Matthews
Ms. Andrea Matthews
Chief Business Officer
Chief Business Officer
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
263.32K
--
Mr. Noah Clauser
Mr. Noah Clauser
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Elizabeth Higgins
Ms. Elizabeth Higgins
Investor Relations
Investor Relations
--
--
Dr. Joanne T. Beck, Ph.D.
Dr. Joanne T. Beck, Ph.D.
Independent Director
Independent Director
--
--
Dr. Jill C. Milne, Ph.D.
Dr. Jill C. Milne, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Sun, Oct 26
마지막 업데이트: Sun, Oct 26
주주
주주 유형
주주
주주
비율
Perceptive Advisors LLC
11.49%
Vestal Point Capital, LP
8.01%
Forbion Capital Partners
7.28%
Fidelity Management & Research Company LLC
6.48%
Magnetar Capital Partners LP
5.87%
기타
60.87%
주주
주주
비율
Perceptive Advisors LLC
11.49%
Vestal Point Capital, LP
8.01%
Forbion Capital Partners
7.28%
Fidelity Management & Research Company LLC
6.48%
Magnetar Capital Partners LP
5.87%
기타
60.87%
주주 유형
주주
비율
Investment Advisor
31.18%
Investment Advisor/Hedge Fund
22.93%
Venture Capital
15.69%
Private Equity
11.49%
Hedge Fund
11.30%
Research Firm
4.23%
Individual Investor
0.49%
Pension Fund
0.17%
Bank and Trust
0.09%
기타
2.43%
기관 주식 보유
마지막 업데이트: Wed, Oct 1
마지막 업데이트: Wed, Oct 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q3
263
57.85M
102.50%
-13.18M
2025Q2
263
60.10M
106.50%
-10.94M
2025Q1
281
59.08M
104.77%
-12.46M
2024Q4
268
59.35M
105.17%
-9.44M
2024Q3
247
57.14M
101.27%
-10.09M
2024Q2
228
56.25M
102.41%
-8.30M
2024Q1
210
58.30M
106.65%
+7.30M
2023Q4
179
37.20M
102.69%
+9.26M
2023Q3
171
23.97M
88.11%
-4.33M
2023Q2
175
25.83M
94.82%
-888.95K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Perceptive Advisors LLC
6.49M
11.49%
--
--
Jun 30, 2025
Vestal Point Capital, LP
4.52M
8.01%
+342.00K
+8.18%
Jun 30, 2025
Forbion Capital Partners
4.11M
7.28%
+285.00K
+7.46%
Jun 30, 2025
Fidelity Management & Research Company LLC
3.66M
6.48%
-1.15M
-23.93%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.18M
5.64%
-222.43K
-6.53%
Jun 30, 2025
Fidelity Institutional Asset Management
2.80M
4.97%
+671.87K
+31.52%
Jun 30, 2025
TCG Crossover Management, LLC
2.76M
4.89%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
2.52M
4.47%
-116.58K
-4.41%
Jun 30, 2025
VR Adviser, LLC
2.46M
4.35%
--
--
Jun 30, 2025
더 보기
관련 ETF
마지막 업데이트: Thu, Nov 6
마지막 업데이트: Thu, Nov 6
이름
비율
Virtus LifeSci Biotech Clinical Trials ETF
0.94%
ALPS Medical Breakthroughs ETF
0.24%
AltShares Merger Arbitrage ETF
0.09%
iShares Micro-Cap ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.03%
Avantis US Small Cap Equity ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
iShares Russell 2000 ETF
0.01%
더 보기
Virtus LifeSci Biotech Clinical Trials ETF
비율0.94%
ALPS Medical Breakthroughs ETF
비율0.24%
AltShares Merger Arbitrage ETF
비율0.09%
iShares Micro-Cap ETF
비율0.05%
ProShares Ultra Nasdaq Biotechnology
비율0.04%
Invesco Nasdaq Biotechnology ETF
비율0.04%
iShares Biotechnology ETF
비율0.03%
Avantis US Small Cap Equity ETF
비율0.03%
iShares Russell 2000 Value ETF
비율0.02%
iShares Russell 2000 ETF
비율0.01%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
날짜
유형
비율
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
